Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) After Bupivacaine Spinal Anesthesia in Subjects Undergoing Elective Cesarean Section

Next Previous
Trial Profile

A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) After Bupivacaine Spinal Anesthesia in Subjects Undergoing Elective Cesarean Section

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary) ; Morphine
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Pacira BioSciences

Most Recent Events

  • 09 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 08 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
  • 08 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Nov 2015 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top